Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PYGL | P06737 | 3/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TTR | P02766 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | RARA | P10276 | 3/20 | 0.33 |
| ▸ | RARB | P10826 | 3/20 | 0.33 |
| ▸ | RARG | P13631 | 3/20 | 0.33 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12365914 | 0.88 | KDM4A (0.40) | TDP1AKR1B1TTRRARB | |
| SCHEMBL12366204 | 0.88 | SRD5A2 (0.46) | TDP1TSHRTTRSRD5A2 | |
| SCHEMBL12366165 | 0.87 | PARP1 (0.39) | — | |
| SCHEMBL12366309 | 0.87 | TDP1 (0.39) | TDP1AKR1B1HTR7 | |
| SCHEMBL12366145 | 0.85 | TDP1 (0.40) | TDP1AKR1B1HCRTR2 | |
| SCHEMBL12366601 | 0.85 | HTR5A (0.49) | HTR7 | |
| SCHEMBL12366273 | 0.84 | TDP1 (0.39) | TDP1AKR1B1TSHRHTR7 | |
| SCHEMBL12366174 | 0.84 | TDP1 (0.41) | TDP1TSHRTTRSRD5A2 | |
| SCHEMBL12390332 | 0.84 | LMNA (0.43) | TDP1PYGLTSHRHTR7 | |
| SCHEMBL12366009 | 0.83 | SRD5A2 (0.40) | TDP1TSHRTTRSRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | TDP1 378/4885PYGL 4343/4885AKR1B1 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.